Trial · NCT00905424
Results by group92
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 92
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Augmentation Baseline for Non-Remitters in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Total Score at Week 6 - Last Observation Carried Forward (LOCF) | Antidepressant + SPD489 (Non-remitters) | -7.1 | Standard Error 0.93 | Units on a scale | |
| Change From Augmentation Baseline for Non-Remitters in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Total Score at Week 6 - Last Observation Carried Forward (LOCF) | Antidepressant + Placebo (Non-remitters) | -4.9 | Standard Error 0.94 | Units on a scale | |
| Change From Augmentation Baseline for Non-Remitters in the Hamilton Depression Scale (HAM-D) Total Score at Week 6 - LOCF | Antidepressant + SPD489 (Non-remitters) | -4.9 | Standard Error 0.64 | Units on a scale | |
| Change From Augmentation Baseline for Non-Remitters in the Hamilton Depression Scale (HAM-D) Total Score at Week 6 - LOCF | Antidepressant + Placebo (Non-remitters) | -4.0 | Standard Error 0.65 | Units on a scale | |
| Change From Augmentation Baseline for Non-Remitters in the Sheehan Disability Scale (SDS) Total Score at Week 6 | Antidepressant + SPD489 (Non-remitters) | -3.7 | Standard Error 0.73 | Units on a scale | |
| Change From Augmentation Baseline for Non-Remitters in the Sheehan Disability Scale (SDS) Total Score at Week 6 | Antidepressant + Placebo (Non-remitters) | -1.7 | Standard Error 0.74 | Units on a scale | |
| Percentage of Non-Remitters With Improvement on Clinical Global Impression-Improvement (CGI-I) at Week 6 - LOCF | Antidepressant + SPD489 (Non-remitters) | 60.0 | Percent of Participants | ||
| Percentage of Non-Remitters With Improvement on Clinical Global Impression-Improvement (CGI-I) at Week 6 - LOCF | Antidepressant + Placebo (Non-remitters) | 45.3 | Percent of Participants | ||
| Assessment in Non-Remitters of Clinical Global Impression-Severity of Illness (CGI-S) at Augmentation Baseline | Antidepressant + SPD489 (Non-remitters) | Normal, not at all ill | 1.5 | Percent of participants | |
| Assessment in Non-Remitters of Clinical Global Impression-Severity of Illness (CGI-S) at Augmentation Baseline | Antidepressant + Placebo (Non-remitters) | Normal, not at all ill | 1.6 | Percent of participants | |
| Assessment in Non-Remitters of Clinical Global Impression-Severity of Illness (CGI-S) at Augmentation Baseline | Antidepressant + SPD489 (Non-remitters) | Borderline mentally ill | 20.0 | Percent of participants | |
| Assessment in Non-Remitters of Clinical Global Impression-Severity of Illness (CGI-S) at Augmentation Baseline | Antidepressant + Placebo (Non-remitters) | Borderline mentally ill | 12.5 | Percent of participants | |
| Assessment in Non-Remitters of Clinical Global Impression-Severity of Illness (CGI-S) at Augmentation Baseline | Antidepressant + SPD489 (Non-remitters) | Mildly ill | 40.0 | Percent of participants | |
| Assessment in Non-Remitters of Clinical Global Impression-Severity of Illness (CGI-S) at Augmentation Baseline | Antidepressant + Placebo (Non-remitters) | Mildly ill | 34.4 | Percent of participants | |
| Assessment in Non-Remitters of Clinical Global Impression-Severity of Illness (CGI-S) at Augmentation Baseline | Antidepressant + SPD489 (Non-remitters) | Moderately ill | 32.3 | Percent of participants | |
| Assessment in Non-Remitters of Clinical Global Impression-Severity of Illness (CGI-S) at Augmentation Baseline | Antidepressant + Placebo (Non-remitters) | Moderately ill | 48.4 | Percent of participants | |
| Assessment in Non-Remitters of Clinical Global Impression-Severity of Illness (CGI-S) at Augmentation Baseline | Antidepressant + SPD489 (Non-remitters) | Markedly ill | 6.2 | Percent of participants | |
| Assessment in Non-Remitters of Clinical Global Impression-Severity of Illness (CGI-S) at Augmentation Baseline | Antidepressant + Placebo (Non-remitters) | Markedly ill | 3.1 | Percent of participants | |
| Assessment in Non-Remitters of Clinical Global Impression-Severity of Illness (CGI-S) at Augmentation Baseline | Antidepressant + SPD489 (Non-remitters) | Severely ill | 0 | Percent of participants | |
| Assessment in Non-Remitters of Clinical Global Impression-Severity of Illness (CGI-S) at Augmentation Baseline | Antidepressant + Placebo (Non-remitters) | Severely ill | 0 | Percent of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00905424/results